BioTuesdays

Tag - Roth Capital Partners

Aptevo Therapeutics

Roth start Aptevo at buy; PT $12

Roth Capital Partners initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and price target of $12. The stock closed at $3.28 on April 11. “In our view, Aptevo remains under the Street’s...

Juniper Pharmaceuticals

Roth doubles Juniper Pharma PT to $24

Roth Capital Partners doubled its price target for Juniper Pharmaceuticals (NASDAQ:JNP) to $24 from $12 after the company reported 2017 results. The stock closed at $10 on March 9. Juniper is focused on developing...

Myomo

Roth starts Myomo at buy; PT $9

Roth Capital Partners initiated coverage of Myomo (NYSE American:MYO) with a “buy” rating and $9 price target. The stock closed at $4.15 on March 8. Analyst Scott Henry writes that the MyoPro robotic arm brace offers...

CymaBay

Roth ups CymaBay price target to $6

Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday. “Following...

TearLab

Roth downgrades TearLab to neutral

Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday. Analyst Chris Lewis writes that TearLab’s second...